Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
暂无分享,去创建一个
W. Choi | J. Winter | M. Piris | G. Bhagat | Y. Zu | K. Young | Z. Xu-Monette | K. Richards | A. Tzankov | M. Møller | J. Huh | G. Manyam | Li Zhang | S. Montes-Moreno | C. Visco | E. Hsi | M. Ponzoni | A. Ferreri | J. V. van Krieken | L. Pham | Jiayu Chen | K. Dybkaer | A. Chiu | A. Orazi | Xiaoying Zhao | Q. Shen | L. Deng | J. Farnen | A. Martínez-López | L. Yin
[1] A. Grañena,et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival , 2015, The Journal of pathology.
[2] P. Went,et al. Phenotype profiling of primary testicular diffuse large B‐cell lymphomas , 2014, Hematological oncology.
[3] Douglas B. Evans,et al. Chemokines and chemokine receptors: update on utility and challenges for the clinician. , 2014, Surgery.
[4] M. Jelen,et al. Decreased Expression of CXCR4 Chemokine Receptor in Bone Marrow after Chemotherapy in Patients with Non-Hodgkin Lymphomas Is a Good Prognostic Factor , 2014, PloS one.
[5] J. Schwaller,et al. CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia , 2014, Leukemia.
[6] R. Horton,et al. Germinal Center Centroblasts Transition to a Centrocyte Phenotype According to a Timed Program and Depend on the Dark Zone for Effective Selection , 2013, Immunity.
[7] W. Choi,et al. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[8] W. Wilson,et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. , 2013, Blood.
[9] A. Dubrovska,et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis , 2013, OncoTargets and therapy.
[10] R. Badolato,et al. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse. , 2013, Blood.
[11] E. Sison,et al. Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML , 2013, Molecular Cancer Research.
[12] W. Choi,et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[13] Arnon Nagler,et al. Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140 , 2013, Clinical Cancer Research.
[14] D. Heckmann,et al. CXCR4 Expression and Treatment with SDF-1α or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells. , 2013, Translational oncology.
[15] W. Choi,et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study , 2013, Haematologica.
[16] W. Choi,et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.
[17] K. Dybkær,et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.
[18] E. D. de Vries,et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. , 2012, Neoplasia.
[19] L. Staudt,et al. Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.
[20] C. Geest,et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.
[21] J. Friedberg. Relapsed/refractory diffuse large B-cell lymphoma. , 2011, Hematology. American Society of Hematology. Education Program.
[22] H. Johnsen,et al. Multiparametric flow cytometry for identification and fluorescence activated cell sorting of five distinct B-cell subpopulations in normal tonsil tissue. , 2011, American journal of clinical pathology.
[23] M. Konopleva,et al. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. , 2011, Blood.
[24] N. Heveker,et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways , 2011, Proceedings of the National Academy of Sciences.
[25] Ido D. Weiss,et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. , 2011, Experimental hematology.
[26] M. Hatano,et al. CXCR4 Expression on Activated B Cells Is Downregulated by CD63 and IL-21 , 2011, The Journal of Immunology.
[27] Jian Zhang,et al. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression , 2010, Cancer and Metastasis Reviews.
[28] R. Gascoyne,et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone , 2010, Leukemia & lymphoma.
[29] E. Lam,et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis , 2010, Haematologica.
[30] M. Sormani,et al. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. , 2009, European journal of cancer.
[31] K. Tarte,et al. CXCR4 Expression Functionally Discriminates Centroblasts versus Centrocytes within Human Germinal Center B Cells1 , 2009, The Journal of Immunology.
[32] E. Estey,et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. , 2009, Blood.
[33] Charles P. Lin,et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. , 2009, Blood.
[34] A. Rosenwald,et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. , 2008, Blood.
[35] A. Ng,et al. Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.
[36] H. Nakshatri,et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion , 2007, Oncogene.
[37] J. Benovic,et al. Regulation of CXCR4 signaling. , 2007, Biochimica et biophysica acta.
[38] M. Oren,et al. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. , 2006, Cancer research.
[39] M. Schuler,et al. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4 , 2006, British Journal of Cancer.
[40] W. Grody,et al. [Diffuse large B-cell lymphoma]. , 2006 .
[41] L. Pham,et al. Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas , 2006 .
[42] Hirokazu Tamamura,et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. , 2005, Blood.
[43] Andreas Radbruch,et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. , 2005, Blood.
[44] F. Balkwill. Cancer and the chemokine network , 2004, Nature Reviews Cancer.
[45] B. Christensen,et al. Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases , 2004, British journal of haematology.
[46] C. Cohen,et al. Post‐translational and cell type‐specific regulation of CXCR4 expression by cytokines , 2003, European journal of immunology.
[47] M. Probst-Kepper,et al. CXCR4/CXCL12 expression and signalling in kidney cancer , 2002, British Journal of Cancer.
[48] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[49] Young-Uk Cho,et al. High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia. , 2014, Leukemia research.
[50] W. Choi,et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2014, Modern Pathology.
[51] Deborah K. Padgett,et al. Data Analysis and Interpretation , 2012 .
[52] S. Fricker,et al. CXCR4 in clinical hematology. , 2010, Current topics in microbiology and immunology.
[53] A Orfao,et al. Human peripheral blood B‐cell compartments: A crossroad in B‐cell traffic , 2010, Cytometry. Part B, Clinical cytometry.
[54] L. Pham,et al. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. , 2006, Blood.